The study of and creation of
therapies that use the immune system of the body to combat cancer are known as
immuno-oncology. Our immune system, which is made up of a complex web of
organs, cells, and molecules, guards us against external invaders like
bacteria, fungus, and viruses that might infect us. The immune system is
capable of locating and eliminating foreign objects as well as attacking
aberrant cells.
The immune system has the best
chance of specifically destroying tumours without harming healthy tissue and
having long-term memory that can stop cancer from coming back. The development
of tumours can be permanently prevented or managed by a mechanism known as
immunosurveillance, according to research in immuno-oncology conducted over the
past 30 years. Recognition of tumour antigens is what gives the immune response
its tumour specificity.
The most well-established
therapeutic class of IO drugs to date, immune checkpoint inhibitors have
demonstrated significant efficacy in treating a variety of cancers. For the
treatment of non-small-cell lung carcinoma, gastric cancer, head and neck
squamous cell carcinoma, and cervical cancer with pembrolizumab (Keytruda,
Merck), as well as for the treatment of urothelial carcinoma with atezolizumab
(Tecentriq, Roche), biomarker testing for the programmed death-ligand 1 (PD-L1)
checkpoint target has been developed and is now required.
Comments
Post a Comment